Pursuant to Regulation 33, please find attached the Financial Results (Standalone and Consolidated) of the Company for the year ended 31.03.2026
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
ZIM Laboratories reported consolidated revenue from operations of Rs. 37,440.01 lakhs for FY26, marginally declining from Rs. 37,903.10 lakhs in FY25. Profit after tax (consolidated) dropped significantly to Rs. 583.81 lakhs from Rs. 1,216.50 lakhs in FY25, a decline of approximately 52%, largely due to higher other expenses and increased finance costs. The auditor's report issued by Deloitte Haskins & Sells LLP carries an unmodified (clean) opinion with no qualifications. Cash and cash equivalents improved sharply to Rs. 2,512.19 lakhs (from Rs. 194.66 lakhs), driven by a preferential equity issue of Rs. 3,507.76 lakhs. Note that Deloitte replaced the previous year's auditor (who audited FY25 results).
The sharp PAT decline (~52%) despite relatively flat revenue signals margin compression and operational challenges. The clean audit provides assurance, but investors should monitor the revenue stagnation and cost inflation trend in subsequent quarters.